Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
